Singapore-listed MetaOptics (Catalist: 9MT) announced on September 20 an investment facility of up to US$10 million from White Lion Capital. White Lion, based in Los Angeles, will hold warrants over 40 million new shares. The release calls it the company’s first U.S. institutional investor and a strong validation of its technology. The MetaOptics investment story, on closer reading, hinges on structure rather than sentiment.
The warrant deed carries a telling phrase. MetaOptics “may, upon exercise of the warrants by the holder at its discretion, raise up to US$10 million.” In plain terms, White Lion — not MetaOptics — decides if and when money arrives. No exercise price appears anywhere in the release. Both facts sit in the text. Both matter more than the headline.
The timing matters too. Two months ago, this company withdrew its planned Nasdaq listing. The facility is what capital-raising looks like after a failed IPO — and its framing deserves scrutiny.
Why the MetaOptics Investment Happened Now
Three events explain the calendar.
The Nasdaq listing that wasn’t
MetaOptics announced its proposed Nasdaq dual listing in November 2025. It filed an F-1 in May 2026, targeting US$33 million at an assumed US$8.15 per ADS, then downsized in June to 3 million ADSs at US$5–7. That cut proceeds by roughly 45%, to about US$18 million.
On August 7, it withdrew the application entirely. The stated reasons: geopolitical uncertainty, tech-stock volatility and “the adverse perception of Asian small-cap issuers” on Nasdaq. Management called the withdrawal “a deferral rather than a change of ambition” and said the company “remains well-capitalised.”
A thin revenue base
FY2025 revenue came in at S$787,388, up 891% year on year. The growth leans heavily on a single direct-laser-writer sale to a Taiwan customer. Net loss for the year: S$5.4 million, including S$2.4 million of one-off listing fees. Cash and unutilized proceeds at year-end: about S$8.8 million.
That base supports a demonstration business. It does not fund a fabrication plant.
The U.S. onshoring pitch
The release says proceeds will fund the Group’s “maiden front-end semiconductor fabrication line” in the U.S. with 12-inch DUV immersion photolithography equipment. Onshoring optics into America is the story Nasdaq investors declined to buy in June. Now it targets a different capital source.
The Competitive Picture: A Minnow Among Whales
The release’s “one of the few companies in the world” claim needs context, because the benchmark competitor sets it.
Metalenz, the Harvard spin-off, is the benchmark. It has shipped more than 300 million meta-optics through STMicroelectronics since 2022. Its Polar ID product reached volume production on UMC’s 40nm process, and it pairs with Samsung sensors. Headcount: roughly 41 employees, running a fabless licensing model.
Research firm QY Research ranks Metalenz, NIL Technology and MetaLenX as the top three metalens makers. Together they hold about 71% of a global market worth roughly US$61 million in 2025. MetaOptics’ S$787,000 of revenue ranks it in a lower tier by absolute size.
The CPO claim needs the same treatment. Broadcom’s 102.4 Tbps co-packaged optics switch, built on TSMC’s silicon photonics, is sampling with early customers. Nvidia’s Quantum-X Photonics switches have started shipping. Samsung targets a turnkey CPO platform for 2029.
MetaOptics says it is “working with several U.S. foundries” on CPO designs. Its smallest CPO metalens to date measures 0.1 mm. The release offers no way to verify either claim.
What the Data Shows About the MetaOptics Investment
The public record fills in what the release leaves blank.
The warrant math
Forty million shares raising US$10 million implies an average price of US$0.25, about S$0.32. The Singapore trading price sat near S$0.79 in mid-2026. That is roughly a 60% discount if the price is fixed, and the arithmetic only gets worse if the warrant carries a variable, market-linked strike. MetaOptics had about 242.6 million shares outstanding, so the facility dilutes existing holders by around 16.5% at maximum. Shareholders have also already approved up to 121.3 million new shares for the (now-withdrawn) ADS offering, plus employee schemes covering 15% of share capital.
Who White Lion actually is
White Lion Capital is a nine-person firm founded in 2019. Its SEC filings with other small-cap clients read like a structured-finance catalogue: equity lines of credit purchased at discounts to market price, commitment fees of US$1.5 million on one US$250 million facility, commitment shares issued on another, senior secured convertible notes carrying a 20% original issue discount and secured by all assets, and a US$400,000 liquidated-damages clause in an OSR Holdings agreement. This is a counterparty that monetizes discounted equity for a living — not a strategic investor whose participation certifies a technology.
The capital history
MetaOptics listed in September 2025 at S$0.20, raising S$6 million gross, then placed S$4.85 million more in December at S$0.7255. The stock ran from S$0.20 to a 52-week high of S$1.49 before settling near S$0.79 — a market capitalization around S$190 million on under S$1 million of annual revenue.
What’s New vs. What’s Repackaged
The MetaOptics investment’s genuinely new elements are the facility itself and the U.S. front-end fab plan, which the release discloses for the first time. Everything else recycles prior announcements.
“Design and evaluation requests from world-class customers” restates the June 2026 shipment of evaluation units to Europe and Japan. The “first pure-play metalens company” framing and the global ranking claims date from IPO documents. Even the “first U.S. institutional investor” line deserves an asterisk: a nine-person structured-finance house is a financing counterparty first.
What stays unclear: the exercise price, any commitment fees, whether the discount triggers Catalist shareholder-approval rules, and how a US$10 million maximum squares with the cost of 12-inch DUV immersion lithography equipment — a class of tool that routinely runs tens of millions of dollars per unit when new.
The Question the Press Release Doesn’t Answer
Start with the number that governs everything: what is the exercise price? Judging the MetaOptics investment without it is impossible, and the release withholds it. The SGXNet announcement of September 21 presumably contains the terms; the marketing version sent to journalists does not.
Then the sequencing puzzle. On August 7, the company said it was “well-capitalised” with a “healthy cash balance.” On September 20, it announced a discretionary equity facility. Both statements can be true — fabs cost money — but six weeks apart, they read as a shift in urgency.
Finally, the capacity question: can US$10 million build a front-end line with immersion lithography, or does the facility merely fund the first deposit on equipment that will require the very U.S. capital markets the company just exited? A purchase order for the fab tools? The release does not mention one.
What the MetaOptics Investment Means for You
If you hold 9MT shares, model the full dilution stack before treating “up to US$10 million” as money in the bank: 40 million facility shares, 121.3 million approved ADS-related shares, and 15% of share capital in employee schemes, against a company that earns under S$1 million a year.
If you follow photonics, treat the CPO narrative with care. The metalens market’s entire 2025 value was roughly US$61 million, and the CPO programs that matter — Broadcom, Nvidia, TSMC, Samsung — are being built by companies with nine-figure capital budgets. A supplier claim of “working with several U.S. foundries” is a starting point for diligence, not a conclusion.
If you evaluate small-cap financings, note the pattern: withdrawn IPO, discretionary warrants, undisclosed strike, and “validation” language attached to a firm whose other deals include 20% discounts and asset-backed notes. The press release is a marketing document. The SGXNet filing is the homework.
Editor’s Note
This article rests on the MetaOptics press release dated September 20, 2026, plus public sources: the company’s SGX Catalist IPO and Nasdaq withdrawal announcements, its FY2025 results release, the March 2026 shareholder circular and EGM results, SEC EDGAR filings for MetaOptics’ F-1 and for White Lion Capital’s other counterparty companies (including CID Holdco, OSR Holdings and CSLR-related filings), Renaissance Capital and other IPO coverage, Simply Wall St market data, QY Research and industry reporting on Metalenz and co-packaged optics. The warrant exercise price, any fees, and the SGXNet announcement’s full terms were not available in the press release and remain unverified. Statements attributed to either company are unverified claims. Nothing here is investment advice.